Compare Enveric Biosciences Inc (ENVB) vs Figs Inc (FIGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Figs Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Figs Inc trades at $14.96 (market cap $2.49B). The key difference: Figs Inc is far larger — about 366.2× Enveric Biosciences Inc's market cap, and Figs Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Figs Inc for 33 Days on average.
| ENVB | FIGS | |
|---|---|---|
Market Cap | $6.80M | $2.49B |
Volume | 64,867 | 5,964,311 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $17.12 |
52-Week Low | $1.27 | $6.90 |
Typical Hold Time | 14 Days | 33 Days |
Enterprise Value | -$1.49M | $2.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
FIGS trades at $14.06, down 0.28% today, with a bullish technical signal from moving averages. The company shows strong revenue growth from $556M in 2024 to $631M in 2025, with net income surging to $34M. Recent quarters have consistently beaten EPS expectations, and international sales grew 67% in Q2 2026. Analyst consensus is bullish with a $18.00 price target suggesting 28% upside potential from current levels.
The outlook remains positive with accelerating growth and margin expansion, though the stock's rich valuation (P/E 42.6) presents risk if execution falters. Key catalysts include continued international expansion and sustained demand from healthcare professionals, while risks include premium valuation pressure and competitive threats in medical apparel.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
